Key facts
- This page summarizes Mark C. Schneyer's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2024, 18:00.
Mark C. Schneyer - 08 Jun 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- EVP, CHIEF FINANCIAL OFFICER
- Issuer ticker
- ACAD
- Reported as of
- 08 Jun 2024
- Net transaction value
- -$14,420
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2024, 18:00:05 UTC
- Prior SEC filing
- 03 May 2024
- Next SEC filing
- 20 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark C. Schneyer filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 11 Jun 2024.
Change
- Previous filing in this sequence was filed on 03 May 2024.
- Current net transaction value: -$14,420.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,893
- Change %
- +5.6%
- Price
- Shares after
- 35,539
- Date
- 08 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ACAD
transaction
Common Stock
Sale
- Transaction value
- $14,420
- Shares
- -975
- Change %
- -2.7%
- Price
- $14.79
- Shares after
- 34,564
- Date
- 10 Jun 2024
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,893
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,893
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
Footnote F3
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.675 to $14.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F5
The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.